Current drug treatments have been incorporated into clinical practice guidelines, such as the NAEPP EPR-3 for asthma [101] and GOLD treatment guidelines for COPD, [102] both of which recognize the ...
Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...
Changing patients from an inhaled corticosteroid (ICS)/long-acting β agonist (LABA) inhaler and long-acting muscarinic agonist (LAMA) inhaler to a LAMA/LABA inhaler and a separate ICS inhaler did not ...
Overall results demonstrated that for the LABA/LAMA cohort cardiovascular event frequency was 2.11% compared to 3.41% in the LABA/ICS cohort. According to a new study published in the Annals of ...
Please provide your email address to receive an email when new articles are posted on . Doubling the inhaled corticosteroid dose and adding umeclidinium to inhaled ...
CHICAGO -- A fixed-dose inhaler combining an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta agonist (ICS/LAMA/LABA) improved lung function and reduced exacerbations in ...
Inhaled corticosteroids (ICSs) are a key incorporation to COPD treatment strategies. Jeffrey D. Dunn, PharmD, MBA: ICSs [inhaled corticosteroids] haven’t shown much evidence in impacting the course of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results